Dineshbhurani

@VincentRK I would like to combine good of both regimens. We have reasonable experience with FLAG-VEN with very high CRc rates and lower mortality. Our data are compared with Paradigm cohort

Given the changes in treatment paradigm for myeloma patients, ASCO guidelines are now updated frequently to catch up for the developments Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1 | 👇@JCO_ASCO @ASCO #mmsm ascopubs.org/doi/pdf/10.120… @bdermanmd @RahulBanerjeeMD @LisaHicksMD @HiraSMian @szusmani @MyelomaTeacher @ZanwarSaurabh @myelomaMD @utswcancer

In a first-in-human phase I clinical trial, CD19/20 cells demonstrated “very strong safety” and efficacy outcomes, with 80% of patients with B-cell #lymphomas achieving complete and durable responses 2 years following treatment. ow.ly/FL4p50Z3gJu #BCL

2/The pick: a phase 3 LBA from Menon's group at Tata Memorial, Mumbai — low-dose pembrolizumab + chemo in advanced NSCLC. Why follow a result we haven't seen? Because of what this exact group has already proven in print.

The Arthaśāstra may contain the earliest documented state-run rainfall measurement system. Long before Korea’s 15th-century Cheugugi and Europe’s 17th-century gauges, it linked ecology, agriculture, taxation, and welfare through evidence-based governance.

Anselamimab is a potential new therapeutic in Kappa AL - abstract now available - countdown to full presentation @ASCO and simultaneous publication @JCO_ASCO on Friday 29th - Anselamimab treated patients with κ iFLC had a 62% reduction in ACM (HR = 0.38; 95% CI, 0.17, 0.86; nominal P = 0.012) and a 71% reduction in risk for CVH (estimated CVH rate ratio = 0.29; 95% CI, 0.10, 0.87; nominal P = 0.028). Patients with λ iFLC had a 10% reduction in risk for CVH; none in ACM. @AlexionPharma @ISA_Amyloidosis @Amyloidosis_ARC

Monetizing Medicine – The Rise of the Celebrity Effect - Bishal Gyawali @oncology_bg oncodaily.com/voices/bishal-…

3/ @ASCO #ASCO26 #myeloma #mmsm - Impact of 5-Year Sustained MRD negativity in FORTE asco.org/abstracts-pres… - cfDNA WGS vs Mass Spec asco.org/abstracts-pres… And one bonus thought-provoking on differences in access to CARTs asco.org/abstracts-pres…

@nikhil91sjmc This absurd order should be revised and updated asap for the betterment of all those who are suffering from blood related disorders. @RahulDoc2 @VergheseRenjith @chepsyphilip @TK2K6 @ishbtish @hematologydr @TikareNakul @Rohanhematdoc

This AAPI Heritage Month, ASH celebrates pioneers whose work transformed hematology. From foundational discoveries in molecular disease to advances in genetic diagnostics, these contributions changed how blood disorders are understood and treated. #AAPIHeritageMonth

This is very strange and surprising that hematologist have been excluded. Across majority of the cities , it is the hematologist only who takes care of acute leukemia. This lack of knowledge on the part of regulatory body is concerning @MoHFW_INDIA @CDSCO_INDIA_INF.

“Long-Term #CLL Treatment: Aligning Patient Priorities With Initiating & Sequencing Targeted Therapy” with Drs. Cramer, Follows, and Woyach on 6/13 at 9:45 AM CEST. Produced with @HealthTree ➡️ bit.ly/Stockholm26-T #EHA2026 #HemOnc

When delivering bad news do not keep patient and family in suspense. Fist ask what they know and then just say the facts calmly. Let the patient and family react and then do your best comfort.

How would you approach these leukemia cases in practice? Join Drs. @Anand_88_Patel, @aditishasMD, @yasminabaza1, @Daver_Leukemia, and Elias Jabbour for a case-based discussion on treatment strategies that matter in real-world care. If you want to see how five of the field's most respected leukemia clinicians think: hubs.ly/Q04f8kbG0  #LLMGreatDebates #Leukemia #Hematology @UTMDAnderson @MontefioreNYC @NorthwesternMed @UChicagoMed

Daratumumab prevents progression of asymptomatic to asymptomatic 5≥60% plasma cells in dara vs 16 in control-no symptoms! 2 anemias in dara vs 14 in control (below arbitrary threshold 2 pts ⬇️ lower limit) 10 cases bone dz in dara vs 18 control 0 fractures/0 renal failure

Hematologists treat acute leukemias at most centers across the country . Excluding hematologists from clinical trials of “HEMATOLOGICAL MALIGNANCIES “ makes absolutely no sense and is an irony in itself . Really unfortunate that instead of widening access to patients , policy decisions ignore ground realities and come up with such absurd ideas @jayastuMD @royjpalatty @VergheseRenjith @chepsyphilip @TK2K6 @ishbtish @hematologydr @TribikramHemat @TikareNakul @Rohanhematdoc @shanuaswam @RahulDoc2 @dranupjdevasia

Thanks @drsanjeev1980 @Rfonsi1 for highlighting this - neat 🇮🇳 analysis of a not-uncommon scenario in myeloma. We've all seen LC-only #MMsm (FLC abnormal, SPEP normal), but what about reverse? M-spike well > 1.0 but FLC totally normal? In this analysis, better prognosis!

Another major dataset questioning routine HD-MTX CNS prophylaxis in aggressive lymphoma. If chemo-resistant biology drives CNS relapse, why would prophylactic MTX suddenly overcome it? Primary disease control remains the best CNS prophylaxis. Testicular lymphoma may be biologically different (MYD88/immune-privileged phenotype). Future prevention may depend more on BTKi/immunotherapy than prophylactic MTX. In biology we trust. 🧬

😁🫡Nice artwork by @BCD_AACR showing the better outcomes with FLAG-GO (longer flag posts) than FLAG-IDA (shorter flag posts)

Has the @CDSCO_INDIA_INF conveniently forgotten that there are #hematologists who are specially trained to treat #bloodcancers ? This order has surprised me as I was a member of the Subject Expert Committee of CDSCO on #HematologyOncology for more than 5 years. If CDSCO feels hematooncologists are not competent to conduct #clinicaltrials on patients with blood cancers then should we stop treating these patients ? @NMC_IND @MoHFW_INDIA @DrPMPGI @RahulDoc2 @drtulikahemat

A painting of the end of meritocracy: A meeting of the two largest economies and not one woman at the table.